Otoimmün Pankreatitin Medikal Yönetimi
Özet
Otoimmün pankreatit (OIP), laboratuvar, histolojik ve morfolojik bulgularla karakterize, nadir görülen ve glukokortikoid tedavisine iyi yanıt veren otoimmün kaynaklı bir hastalıktır. Hastalık, lenfoplazmasitik sklerozan pankreatit olarak bilinen ve IgG4 ilişkili hastalık sendromunun bir parçası olabilen Tip 1 ile idiyopatik kanal merkezli pankreatit olarak tanımlanan ve inflamatuar barsak hastalığıyla ilişkilendirilen Tip 2 olmak üzere iki histolojik alt tipe ayrılır. Tanı sürecinde klinik semptomların yanı sıra laboratuvar testleri, ileri görüntüleme yöntemleri ve malignitelerin dışlanması için biyopsi bulgularını içeren HISORt kriterleri kullanılır. Semptomatik hastalarda veya vital organ sekelleri riski taşıyan asemptomatik vakalarda ilk seçenek olarak 4-6 haftalık yüksek doz prednizon tedavisi uygulanır. Tedaviye yanıt alındıktan sonra steroid dozu kademeli olarak azaltılarak toplam süreç genellikle 12 haftada tamamlanır. Tip 1 hastalarda nüks oranı daha yüksek olup, steroid doz azaltımı veya kesilmesi döneminde yaşanan alevlenmelerde düşük doz glukokortikoidler, tiopürinler veya ritüksimab gibi alternatif ajanlar tercih edilir. Nüks riski yüksek olan hastalarda uzun süreli idame tedavisi ve düzenli laboratuvar ile görüntüleme takipleri gerekirken, uzun dönemde gelişebilecek pankreas endokrin ve ekzokrin yetmezliği gibi komplikasyonların yönetimi de tedavi başarısı açısından kritik öneme sahiptir.
Autoimmune pancreatitis (AIP) is a rare fibroinflammatory disease characterized by specific laboratory, histological, and morphological findings, showcasing a highly favorable response to glucocorticoid therapy. AIP is classified into two distinct histological subtypes: Type 1, known as lymphoplasmacytic sclerosing pancreatitis, which frequently manifests as a component of systemic IgG4-related disease, and Type 2, defined as idiopathic duct-centric pancreatitis, which is often associated with inflammatory bowel disease. Diagnosis relies on clinical symptoms, laboratory evaluations, advanced imaging, and biopsy findings categorized under the HISORt criteria to effectively rule out pancreatic malignancies. Indication for treatment includes symptomatic presentations or specific asymptomatic criteria; induction therapy consists of a high-dose prednisone regimen for 4-6 weeks, followed by a gradual tapering over a total duration of 12 weeks. Relapse rates are significantly higher in Type 1 AIP. In cases of steroid-dependent disease or disease flares during tapering, low-dose glucocorticoids, thiopurines, or rituximab are utilized for maintenance. High-risk patients require long-term maintenance therapy and close surveillance via biochemical and radiological follow-ups. Concomitantly, managing long-term complications, such as endocrine and exocrine pancreatic insufficiency, remains a cornerstone of comprehensive patient care.
Referanslar
Hart PA, Zen Y, Chari ST. Recent Advances in Autoimmune Pancreatitis. Gastroenterology.2015;149(1):39-51. doi:10.1053/j.gastro.2015.03.010
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-358. doi:10.1097/MPA.0b013e3182142fd2
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30. doi:10.1007/s10165-011-0571-z
de Pretis N, Frulloni L. Autoimmune pancreatitis type 2. Curr Opin Gastroenterol.2020;36(5):417-420. doi:10.1097/MOG.0000000000000655
de Pretis N, Vieceli F, Brandolese A, Brozzi L, Amodio A, Frulloni L. Autoimmune pancreatitis not otherwise specified (NOS): Clinical features and outcomes of the forgotten type. Hepatobiliary Pancreat Dis Int. 2019;18(6):576-579. doi:10.1016/j.hbpd.2019.05.010
Kawa S, Kamisawa T, Notohara K, et al. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas. 2020;49(1):e13-e14. doi:10.1097/MPA.0000000000001443
Kurita A, Yasukawa S, Zen Y, et al. Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc. 2020;91(2):373-381.e2. doi:10.1016/j.gie.2019.10.012
Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7(10):1097-1103. doi:10.1016/j.cgh.2009.04.020
Kuraishi Y, Uehara T, Watanabe T, et al. Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis. Pancreatology. 2020;20(6):1062-1068. doi:10.1016/j.pan.2020.07.408
Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17(1):1-6. doi:10.1016/j.pan.2016.12.003
Kubota K, Kamisawa T, Hirano K, et al. Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci. 2018;25(4):223-230. doi:10.1002/jhbp.541
Buijs J, van Heerde MJ, Rauws EA, et al. Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas. 2014;43(2):261-267. doi:10.1097/MPA.0000000000000044
Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56(12):1719-1724. doi:10.1136/gut.2006.115246
Majumder S, Takahashi N, Chari ST. Autoimmune Pancreatitis. Dig Dis Sci. 2017;62(7):1762-1769. doi:10.1007/s10620-017-4541-y
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607-1615. doi:10.1136/gutjnl-2012-302886
Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487-494. doi:10.1136/gutjnl-2016-312049
Soliman H, Vullierme MP, Maire F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United European Gastroenterol J. 2019;7(8):1073-1083. doi:10.1177/2050640619862459
